Do we still need chemotherapy for AIDS-associated Kaposi's sarcoma?

被引：1
|
作者：
Dalla Pria, Alessia [1 ]
Hayward, Katy [1 ]
Bower, Mark [1 ]
机构：
[1] Chelsea & Westminster Hosp, Natl Ctr HIV Malignancy, London SW10 9NH, England
来源：
EXPERT REVIEW OF ANTICANCER THERAPY | 2013年 / 13卷 / 02期
关键词：
AIDS; antiretrovirals; chemotherapy; HIV; Kaposi sarcoma; ACTIVE ANTIRETROVIRAL THERAPY; RECONSTITUTION INFLAMMATORY SYNDROME; PEGYLATED-LIPOSOMAL DOXORUBICIN; VASCULAR-PERMEABILITY FACTOR; PHASE-III TRIAL; IMMUNE RECONSTITUTION; DNA-SEQUENCES; MALIGNANCY CONSORTIUM; INFECTED INDIVIDUALS; PROTEASE INHIBITORS;
D O I：
10.1586/ERA.12.179
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The widespread introduction of effective combination antiretroviral therapy (cART) has had a major influence on the epidemiology and natural history of AIDS-associated Kaposi's sarcoma (AIDS-KS). cART has reduced the incidence of AIDS-KS, and it has been shown to be an effective treatment for early-stage KS. So with the widespread availability of cART, is systemic chemotherapy still required for AIDS-KS? Two indications appear to remain: advanced-stage AIDS-KS and patients who have progressive KS despite effective cART including immune reconstitution inflammatory syndrome KS.
引用
收藏
页码：203 / 209
页数：7
相关论文
共 50 条
  • [41] Molecular characterization of Kaposi's sarcoma associated herpesvirus (KSHV) from patients with AIDS-associated Kaposi's sarcoma in Sao Paulo, Brazil
    Nascimento, MC
    Wilder, N
    Pannuti, CS
    Weiss, HA
    Mayaud, P
    JOURNAL OF CLINICAL VIROLOGY, 2005, 33 (01) : 52 - 59
  • [42] Identification of AIDS-Associated Kaposi Sarcoma: A Functional Genomics Approach
    Zhang, Peng
    Wang, Jiafeng
    Zhang, Xiao
    Wang, Xiaolan
    Jiang, Liying
    Gu, Xuefeng
    FRONTIERS IN GENETICS, 2020, 10
  • [43] AIDS-associated Kaposi sarcoma in Uganda: response to treatment with highly active antiretroviral therapy and chemotherapy
    HQ Nguyen
    F Okuku
    F Ssewankambo
    AS Magaret
    C Johnston
    A Wald
    A Kambugu
    L Corey
    J Orem
    C Casper
    Infectious Agents and Cancer, 4 (Suppl 2)
  • [44] INFECTIOUS AND GENETIC-FACTORS IN AIDS-ASSOCIATED KAPOSI SARCOMA
    GOEDERT, JJ
    LANCET, 1990, 335 (8688): : 547 - 547
  • [45] A novel mathematical model of AIDS-associated Kaposi's sarcoma: Analysis and optimal control
    Kaondera-Shava, R. F.
    Lungu, E.
    Szomolay, B.
    BIOSYSTEMS, 2021, 200
  • [46] Validation and refinement of the ACTG staging system for AIDS-associated Kaposi's sarcoma (KS).
    Krown, SE
    Huang, J
    Testa, M
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1997, 14 (04): : 19 - 19
  • [47] Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy
    Holkova, B
    Takeshita, K
    Cheng, DM
    Volm, M
    Wasserheit, C
    Demopoulos, R
    Chanan-Khan, A
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) : 3848 - 3851
  • [48] Desferrioxamine enhances aids-associated Kaposi's sarcoma tumor development in a xenograft model
    Simonart, T
    Boelaert, JR
    Andrei, G
    Van Den Oord, JJ
    Degraef, C
    Hermans, P
    Noel, JC
    Van Vooren, JP
    Heenen, M
    De Clercq, E
    Snoeck, R
    INTERNATIONAL JOURNAL OF CANCER, 2002, 100 (02) : 140 - 143
  • [49] Influence of highly active antiretroviral therapy on the evolution of AIDS-associated Kaposi's sarcoma
    Alsina, MM
    Bulla, F
    Conill, C
    Mallolas, J
    Pérez-Cuevas, JB
    Lecha, M
    MEDICINA CLINICA, 2000, 115 (19): : 736 - 737
  • [50] Indocyanine green and laser light for the treatment of AIDS-associated cutaneous Kaposi's sarcoma
    C Abels
    S Karrer
    W Bäumler
    AE Goetz
    M Landthaler
    R-M Szeimies
    British Journal of Cancer, 1998, 77 : 1021 - 1024
12345